The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate

Haematologica

Volumn 88, Issue 8, 2003, Pages 853-863

  Gatto, Simona ^a   Scappini, Barbara ^a   Pham, Lan ^a   Onida, Francesco ^a   Milella, Michele ^a   Ball, Greg ^b   Ricci, Clara ^a   Divoky, Vladimir ^c   Verstovsek, Srdan ^a   Kantarjian, Hagop M ^a   Keating, Michael J ^a   Cortes, Jorge E ^a   Beran, Miloslav ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

CML; PS 341; STI571 resistant cell lines

Indexed keywords

APOPTIN; BCR ABL PROTEIN; BORTEZOMIB; CASPASE 3; DNA; I KAPPA B ALPHA; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; PROPIDIUM IODIDE; PROTEASOME INHIBITOR;

APOPTOSIS; ARTICLE; ASSAY; CELL ACTIVITY; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA BINDING; DNA CONTENT; DOWN REGULATION; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; DRUG SENSITIVITY; ENZYME ACTIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; LYMPHATIC LEUKEMIA; PHOSPHORYLATION; PROTEIN BINDING; SEQUENTIAL ANALYSIS; STAINING; WESTERN BLOTTING;

APOPTOSIS; BORONIC ACIDS; CASPASE 3; CASPASES; CELL CYCLE; CELL LINE, TUMOR; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; DNA-BINDING PROTEINS; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ABL; HUMANS; I-KAPPA B PROTEINS; LEUKEMIA, LYMPHOCYTIC; LEUKEMIA, MYELOID; MULTIENZYME COMPLEXES; NF-KAPPA B; PHOSPHORYLATION; PIPERAZINES; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; PYRIMIDINES;

EID: 0141761420     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med 1999;341:164-72.
2. Westbrook CA, Hooberman AL, Spino C, Dodge RK, Larson RA, Davey F, et al. Clinical significance of the Bcr-Abl fusion gene in adult acute lymphoblastic leukemia: a cancer and leukemia group B study (8762). Blood 1992;80:2983-90.
3. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210 BCR/ABL gene of the Philadelphia chromosome. Science 1990;247:824-30.
4. Heisterkamp N, Jenster G, Ten Hoeve J, Zovich D, Pattengale PK, Groffen J. Acute leukemia in BCR/ABL transgenic mice. Nature 1990;344:251-3.
5. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal G, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cell. Nat Med 1996;2:561-6.
6. Buchdunger E, Zimmerman J, Mett H, Meyer T, Muller M, Druker BJ, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996;56:100-4.
7. Deininger MWN, Goldman JM, Lydon N, and Melo JV. The tyrosine kinase inhibitor STI571 selectively inhibits the growth of BCR/ABL positive cells. Blood 1997;90:3691-8.
8. Kantarjian H, Sawyers C, Hochlaus A, Guilhot F, Schiffer C, Resta D, et al. Phase II study of STI 571, a tyrosine kinase inhibitor, in patients (pts) with resistant or refractory Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML). Blood 2000;96:11 Suppl 1:470a [abstract].
9. Sawyers C, Hochlaus A, Feldman E, Goldman JM, Miller C, Ben-Am M, et al. A phase II study to determine the safety and antileukemic effects of STI 571 in patients with Philadelphia chromosome positive chronic myeloid leukemia in myeloid blast crisis. Blood 2000;96:11 Suppl 1:503a [abstract].
10. Ottmann OG, Sawyers C, Druker B, Reiffers J, Goldman JM, O'Brien SG, et al. A phase II study to determine the safety and antileukemic effects of STI 571 in adult patients with Philadelphia chromosome positive acute leukemias. Blood 2000;96:11 Suppl 1:828a[abstract].
11. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
12. Druker BJ, Sawyers CL, Kantarjian H, Resta D, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
13. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99:1928-37.
14. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-22.
15. Adams J, Palombella VJ, Elliott PJ. Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs 2000;18:109-21.
16. King RW, Deshaies RJ, Peters JM, Kirschner MV. How proteolysis drives the cell cycle. Science 1996;274:1652-9.
17. Jonuleit T, van der Kuip H, Miething C, Michels H, Hallek M, Duyster J, et al. Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines. Blood 2000;96:1933-9.
18. Beg AA, Baltimore D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science 1996;274:782-4.
19. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-α-induced apoptosis by NF-κB. Science 1996;274:787-9.
20. Wang CY, Mayo MW, Baldwin AS. TNF-α and cancer therapy induced apoptosis: potentiation by inhibition of NF-κB. Science 1996;274:784-7.
21. Karin M, Lin A. NF-κB at the crossroads of life and death. Nat Immunol 2002;3:221-7.
22. Sanchez Garcia I, Grutz G. Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc Natl Acad Sci USA 1995;92:5287-91.
23. Amarante-Mendes G, Mcgahon A, Nishioka W, Afar D, Witte O, Green D. Bcl-2 independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xl. Oncogene 1998;16:1383-98.
24. Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin AS. A requirement for NF-κB activation in Bcr/Abl-mediated transformation. Genes Dev 1998;12:968-81.
25. Hamdane M, David-Cordonnier MH, D'Halluin JC. Activation of p65 NF-κB protein by p210BCR-ABL in a myeloid cell line (P210BCR-ABL activates p65 NF-κB). Oncogene 1997;15:2267-75.
26. Ping Dou Q, McGuire TF, Peng Y, An B. Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells. J Pharmacol Exp Ther 1999;289:781-90.
27. Le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita C, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000;95:1758-66.
28. Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000;95:3498-505.
29. Mahon FX, Deininger MWN, Schultheis B, Chabrol J, Reiffers J, Goldman JM, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000;96:1070-9.
30. Ricci C, Scappini B, Divoky V, Gatto S, Onida F, Kantarjian H, et al. Mutation in the ATP-binding pocket of the Abl kinase domain in an STI571 resistant BCR-ABL positive cell line. Cancer Res 2002;62:5995-8.
31. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by Bcr-Abl gene mutation or amplification. Science 2001;293:876-80.
32. Hochlaus A, Kreil S, Corbin A, La Rosee P, Lahaye T, Berger U, et al. Roots of clinical resistance to STI-571 cancer therapy. Science 2001;293:2163.
33. Barthe C, Cony-Makhou P, Melo JV, Mahon JR. Roots of clinical resistance to STI-571 cancer therapy. Science 2001;293:2163.
34. Von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukemia to STI571: a prospective study. Lancet 2002;356:487-91.
35. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-6.
36. Cusack JC, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implication for systemic nuclear factor-κB inhibition. Cancer Res 2001;61:3535-40.
37. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999;5:2638-45.
38. Sunwoo JB, Chen Z, Dong G, Yeh N, Bancroft CC, Sausville E, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-κB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001;7:1419-28.
39. Beran M, Pisa P, O'Brien S, Kurzrock R, Siciliano M, Cork A, et al. Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from a chronic myelogenous leukemia cells in the blastic phase. Cancer Res 1993;53:1-9.
40. Wetzler M, Talpaz M, Van Etten RA, Hirsch-Ginsberg C, Beran M, Kurzrock R. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J Clin Invest 1993;92:1925-39.
41. Andersson BS, Beran M, Pathak S, Goodacre A, Barlogie B, and McCredie KB. Ph-positive chronic myeloid with near-haploid conversion in vivo and establishment of a continuously growing cell line with similar cytogenetic pattern. Cancer Genet Cytogenet 1987;24:335-43.
42. Estrov Z, Talpaz M, Zipf TF, Kantarjian HM, Ku S, Ouspenskaia MV, et al. Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph)-positive lymphoblastic leukemia: studies on two newly established Ph-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181). J Cell Physiol 1996;166:618-30.
43. Soligo D, Servida F, Delia D, Fontanella E, Lamorte G, Caneva L, et al. The apoptogenic response of human mycloid leukemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI. Br J Haematol 2001;113:126-35.
44. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. PNAS 2002;99:14374-9.